Sales pressure on active pharmaceutical ingredients from the emergence of authorized generics, mainly for major products
First written in FY2018-Q1. 3 of 6 entries say "Restated". Latest entry: FY2019.
0 other companies' latest entry also says "Dropped".
- FY2019DroppedAnnual reportThe report contains no specific description of the emergence of AGs, particularly for major products, as a source of pressure on active pharmaceutical ingredient sales.
- FY2019-Q1RestatedAnnual report
「Sales of active pharmaceutical ingredients for certain generic drugs, including active ingredients for antihypertensive drugs and anti-inflammatory analgesics, remained solid. Overall, however, conditions remained difficult due to the effects of efforts to optimize drug use in medical settings and the emergence of AGs, particularly for major products.」
While sales of certain products remained solid, pressure on active pharmaceutical ingredient sales from efforts to optimize drug use and the emergence of AGs, particularly for major products, continues to be described. - FY2018WorsenedAnnual report
「Sales of active pharmaceutical ingredients for certain generic drugs, including active ingredients for peptic ulcer treatments and antihypertensive drugs, remained solid. Overall, however, conditions remained difficult due to the effects of efforts to optimize drug use in medical settings, the emergence of AGs (authorized generics), particularly for major products, and intensifying market competition. Net sales were ¥20,848 million, down 6.4% year on year.」
Pressure on active pharmaceutical ingredient sales from the emergence of AGs, efforts to optimize drug use and intensifying market competition was quantified as a 6.4% year-on-year decline in full-year net sales. - FY2018-Q3RestatedAnnual report
「Sales of active pharmaceutical ingredients for certain generic drugs, including active ingredients for peptic ulcer treatments and antihypertensive drugs, remained solid. Overall, however, conditions remained difficult due to the effects of efforts to optimize drug use in medical settings and the emergence of AGs (authorized generics), particularly for major products.」
Pressure on active pharmaceutical ingredient sales from efforts to optimize drug use in medical settings and the emergence of AGs, particularly for major products, continues to be described. - FY2018-Q2RestatedAnnual report
「Sales of active pharmaceutical ingredients for certain generic drugs, including active ingredients for peptic ulcer treatments and antihypertensive drugs, remained solid. Overall, however, conditions remained difficult due to the effects of efforts to optimize drug use in medical settings and the emergence of AGs (authorized generics), particularly for major products.」
Pressure on active pharmaceutical ingredient sales from efforts to optimize drug use in medical settings and the emergence of AGs, particularly for major products, continues to be described. - FY2018-Q1First statedAnnual report
「Sales of active pharmaceutical ingredients for certain generic drugs, including active ingredients for peptic ulcer treatments and antihypertensive drugs, remained solid. Overall, however, conditions remained difficult due to the effects of efforts to optimize drug use in medical settings and the emergence of AGs (authorized generics), particularly for major products.」
The effects of efforts to optimize drug use in medical settings and the emergence of AGs, particularly for major products, are described specifically for the first time as factors making generic active pharmaceutical ingredient sales difficult in practice.